Skip to content

Anesthetic Approaches for Dacryocystorhinostomy Surgery: The Effect of Adding Local Anesthesia to General Inhalational Anesthesia

The Efficacy of Combined Local and General Anesthesia or General Anesthesia Alone in External Dacryocystorhinostomy: A Randomized Controlled Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04300595
Enrollment
24
Registered
2020-03-09
Start date
2020-04-01
Completion date
2023-07-30
Last updated
2023-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effects of; Anesthesia, Local,Pain,in DISE

Brief summary

To Study the effect of combination of of general anesthesia and local anesthesia in anesthesia for external dacryocystorhinostomy and assess quality of the procedure

Detailed description

* calculate the total requirement for anaesthetic agents to maintain satisfactory operating conditions * calculate total anesthetic time * assess intraoperative changes in hemodynamics * assess intraoperative blood loss * evaluate surgeon and patient satisfaction * recognize whether this was related with changes in postoperative analgesia . * Also occurrence of postoperative nausea was recorded and compared with general anaesthesia combined with intravenous opioid for (EXT-DCR) surgery.

Interventions

PROCEDURECombination of General anesthesia and local anesthesia in dacryocystorhinostomy surgery

all patients were assigned randomly to receive either general anesthesia with intravenous opioids and local infiltration of saline (Group G) or general anesthesia with intravenous saline and local infiltration of a mixture of lidocaine/epinephrine (Group L). In both groups, general anesthesia was induced with 2 mg/kg propofol and tracheal intubation was facilitated by 0.1 mg/kg cisatracurium. All patients underwent mechanical ventilation with 100% oxygen. Anesthesia was maintained with isoflurane, and muscle relaxation was provided by an injection of cisatracurium 0.02 mg/kg every 20 minutes.

Sponsors

Zagazig University
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

In the Group G, Local infiltration of 10 ml normal saline at site of skin incision after marking and analgesia was provided by 40 µg/kg nalbuphine loaded in 10 ml syringe IV before skin incision and subsequent injections of 10-20 µg/kg nalbuphine as necessary. The last supplemental bolus of nalbuphine was given at least 30 min before the end of the operation In the Group L, Local infiltration of 10 ml mixture of 20 mg/ml lidocaine and 10 µg/ml epinephrine (instead of saline used in Group G) and normal saline in 10 ml syringe was given IV (instead of nalbuphine used in Group G).

Intervention model description

The day before surgery and after obtaining written informed consent and full history taking, all patients were assigned randomly to receive either general anesthesia with intravenous opioids and local infiltration of saline (Group G) or general anesthesia with intravenous saline and local infiltration of a mixture of lidocaine/epinephrine (Group L).

Eligibility

Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

• Age from 20 to 50 years old. * American society of anesthesiologists (ASA) physical status I or II. * Elective unilateral Dacryocystorhinostomy with paranasal skin incision.

Exclusion criteria

* Endoscopic Dacryocystorhinostomy. * Allergy to amide local anesthetics or opioids. * Drug abuse. * Pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
postoperative pain assessmentchange in visual analogue scale at 1, 2, 4, 6, 8, 12, and 24 hours postoperative after extubationTo quantify the intensity of postoperative pain, the patients were asked to use a 10-cm visual analog scale (VAS) grade from 0-cm (no pain) to 10-cm (the worst possible pain) 1, 2, 4, 6, 8, 12, and 24 h after extubation
hemodynamic assessmentfor 24 hoursChange in heart rate were recorded preoperatively, after induction of general anesthesia, after IV injection of 10 ml syringe and after local infiltration, then every 5 min intraoperatively, and during early recovery, and every 30 min, thereafter for 24 hours

Secondary

MeasureTime frameDescription
time to rescue analgesiaup to 24 hours of postoperativeThe time from the end of anaesthesia to first use of rescue analgesia (nalbuphine)
The number of patients who required nalbuphine in the postoperative period,up to 24 hours of postoperativeto calculate the number of patients who required nalbuphine in the postoperative period,
extubation timeintraoperative (from time of anesthesia ended till extubation and recorded in each patient in minutes)Extubation time was calculated from time of anesthesia off till extubation and recorded in each patient
patient and surgeon satisfactionassessed on the first postoperative day from both patients and surgeons.An overall satisfaction score according to postoperative analgesia . * nil = 0 * mild = 1 * good = 2 * excellent = 3 was recorded on the first postoperative day from both patients and surgeons. The acceptance of combination of LA and GA was questioned and the patients who applied for a successive operation on the other eye were recorded
intraoperative bleedingat the end of surgeryto the nearest milliliter) was determined by the amount of blood in the suction containers and gauze sponges, based on assessment by the surgeon.
mean isoflurane %intraoperative ( recorded every 5 minutes)Isoflurane concentration was adjusted according to hemodynamics by increase or decrease concentration when heart rate or mean arterial blood pressure increase or decrease more than 20-30% of the basal preoperative record, respectively and after nalbuphine dose failed to adjust hemodynamics

Countries

Egypt

Contacts

Primary ContactHeba M EL-Asser, MD
aseeaswad1@yahoo.com00201062393152
Backup Contactamr sh Elshafei, MD
amrshaaban85@gmail.com00201225800795

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026